Edesa Biotech EV/EBITDA
What is the EV/EBITDA of Edesa Biotech?
The EV/EBITDA of Edesa Biotech, Inc. is N/A
What is the definition of EV/EBITDA?
EV/EBITDA is enterprise value divided by earnings before interest, tax, depreciation, and amortization. It is a measure of how expensive a stock is and is more frequently valid for comparisons across companies than the price to earnings ratio. It measures the price (in the form of enterprise value) an investor pays for the benefit of the company’s cash flow (in the form of EBITDA).
= enterprise value / EBITDA
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA of companies in the Health Care sector on NASDAQ compared to Edesa Biotech
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Companies with ev/ebitda similar to Edesa Biotech
- Bambuser AB (publ) has EV/EBITDA of N/A
- Nevada Metals has EV/EBITDA of N/A
- Elys Game Technology has EV/EBITDA of N/A
- Velodyne Lidar has EV/EBITDA of N/A
- Blue Sky Alternative Investments has EV/EBITDA of N/A
- Arix Bioscience plc has EV/EBITDA of N/A
- Edesa Biotech has EV/EBITDA of N/A
- Shenzhen Neptunus Interlong Bio-technique has EV/EBITDA of N/A
- Baumot AG has EV/EBITDA of N/A
- Discovery Harbour Resources has EV/EBITDA of N/A
- Guardion Health Sciences Inc has EV/EBITDA of N/A
- Taronis Fuels has EV/EBITDA of N/A
- DQ Entertainment (International) has EV/EBITDA of N/A